Literature DB >> 30690184

The prion-like spreading of α-synuclein: From in vitro to in vivo models of Parkinson's disease.

Jessica Y Vargas1, Clara Grudina1, Chiara Zurzolo2.   

Abstract

Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease. PD is characterized by the loss of dopaminergic neurons, primarily in brain regions that control motor functions, thereby leading to motor impairments in the patients. Pathological aggregated forms of the synaptic protein, α-synuclein (α-syn), are involved in the generation and progression of PD. In PD brains, α-syn accumulates inside neurons and propagates from cell-to-cell in a prion-like manner. In this review, we discuss the in vitro and in vivo models used to study the prion-like properties of α-syn and related findings. In particular, we focus on the different mechanisms of α-syn spreading, which could be relevant for the development of alternative therapeutic approaches for PD treatment.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Neurobiology; Neurodegeneration; Parkinson’s disease; Prion-like behavior; α-Synuclein

Mesh:

Substances:

Year:  2019        PMID: 30690184     DOI: 10.1016/j.arr.2019.01.012

Source DB:  PubMed          Journal:  Ageing Res Rev        ISSN: 1568-1637            Impact factor:   10.895


  18 in total

1.  α-Synuclein fibrils subvert lysosome structure and function for the propagation of protein misfolding between cells through tunneling nanotubes.

Authors:  Aysegul Dilsizoglu Senol; Maura Samarani; Sylvie Syan; Carlos M Guardia; Takashi Nonaka; Nalan Liv; Patricia Latour-Lambert; Masato Hasegawa; Judith Klumperman; Juan S Bonifacino; Chiara Zurzolo
Journal:  PLoS Biol       Date:  2021-07-20       Impact factor: 8.029

Review 2.  α-Synuclein aggregation and transmission in Parkinson's disease: a link to mitochondria and lysosome.

Authors:  Rui Wang; Hongyang Sun; Haigang Ren; Guanghui Wang
Journal:  Sci China Life Sci       Date:  2020-07-15       Impact factor: 6.038

3.  Slowing Parkinson's Disease Progression with Vaccination and Other Immunotherapies.

Authors:  Dhanya Vijayakumar; Joseph Jankovic
Journal:  CNS Drugs       Date:  2022-02-25       Impact factor: 5.749

Review 4.  Association of Glial Activation and α-Synuclein Pathology in Parkinson's Disease.

Authors:  Rui Wang; Haigang Ren; Elena Kaznacheyeva; Xiaojun Lu; Guanghui Wang
Journal:  Neurosci Bull       Date:  2022-10-14       Impact factor: 5.271

5.  Binding Stability of Antibody-α-Synuclein Complexes Predicts the Protective Efficacy of Anti-α-synuclein Antibodies.

Authors:  Matthias Höllerhage; Andreas Wolff; Tasnim Chakroun; Valentin Evsyukov; Linghan Duan; Oscar Wing-Ho Chua; Qilin Tang; Thomas Koeglsperger; Günter U Höglinger
Journal:  Mol Neurobiol       Date:  2022-04-22       Impact factor: 5.682

6.  α-Synuclein induced cholesterol lowering increases tonic and reduces depolarization-evoked synaptic vesicle recycling and glutamate release.

Authors:  Vesna Lazarevic; Yunting Yang; Wojciech Paslawski; Per Svenningsson
Journal:  NPJ Parkinsons Dis       Date:  2022-06-07

7.  The dual role of c-src in cell-to-cell transmission of α-synuclein.

Authors:  Yu Ree Choi; Jae-Bong Kim; Seo-Jun Kang; Hye Rin Noh; Ilo Jou; Eun-Hye Joe; Sang Myun Park
Journal:  EMBO Rep       Date:  2020-05-05       Impact factor: 8.807

Review 8.  Peering into tunneling nanotubes-The path forward.

Authors:  Diégo Cordero Cervantes; Chiara Zurzolo
Journal:  EMBO J       Date:  2021-03-01       Impact factor: 11.598

9.  Internalization of α-synuclein oligomers into SH-SY5Y cells.

Authors:  Lindsay J Shearer; Nils O Petersen; Michael T Woodside
Journal:  Biophys J       Date:  2021-01-28       Impact factor: 4.033

Review 10.  Neurodegenerative disorders and gut-brain interactions.

Authors:  Alpana Singh; Ted M Dawson; Subhash Kulkarni
Journal:  J Clin Invest       Date:  2021-07-01       Impact factor: 19.456

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.